• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleo

tetano

Editor, Senior Moderator
J Med Virol


. 2024 Aug;96(8):e29826.
doi: 10.1002/jmv.29826. Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2

Serge Ouoba[SUP] 1 2 [/SUP], Aya Sugiyama[SUP] 1 [/SUP], Ko Ko[SUP] 1 [/SUP], Ulugbek Khudayberdievich Mirzaev[SUP] 1 3 [/SUP], Kanon Abe[SUP] 1 [/SUP], Bunthen E[SUP] 1 4 [/SUP], Zayar Phyo[SUP] 1 [/SUP], Kobiljon Khusniddin Khalilov[SUP] 1 [/SUP], Akemi Kurisu[SUP] 1 [/SUP], Tomoyuki Akita[SUP] 1 [/SUP], Kazuaki Takahashi[SUP] 1 [/SUP], Hiroshi Sasaki[SUP] 5 [/SUP], Takumi Yamamoto[SUP] 5 [/SUP], Junko Tanaka[SUP] 1 [/SUP]



Affiliations
Abstract

Commercially available assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) or anti-nucleocapsid (N) antibodies differ in units, making results comparisons challenging. This study aimed to develop conversion equations between five quantitative anti-S antibody tests and to assess the agreement over time between three qualitative anti-N antibody tests. Blood samples from 24 216 vaccinated healthcare workers in Hiroshima Prefecture, Japan, were analyzed for anti-S antibodies using five quantitative tests (Abbott, Fujirebio, Ortho, Sysmex, Roche) and for anti-N antibodies using three qualitative tests (Abbott, Sysmex, Roche). Geometric mean regression was performed to establish equations for converting measured values between the five quantitative tests. Fleiss κ statistic was used to assess the agreement between the three qualitative tests. A strong correlation (Pearson's coefficient r > 0.9) was found for each pair of the five quantitative tests measuring anti-S antibodies, enabling the development of equations to convert values between each pair. Using these equations, which are based on the original output unit of each test, values obtained from one test can be transformed to be equivalent to the corresponding values in another test. For the three tests for anti-N antibodies, the agreement was substantial in the total sample (Fleiss' κ, 0.74) and moderate among those with self-reported past coronavirus disease 2019 (COVID-19) infection (Fleiss' κ, 0.39). The agreement decreased with time after infection. Reduced agreement between anti-N antibodies tests over time suggests caution in comparing seroepidemiological studies of COVID-19 exposure based on anti-N antibodies measurement. The findings could help improve antibody measurement systems and inform public health decision-makers.

Keywords: SARS‐CoV‐2; agreement; antibody; conversion.

 
Back
Top Bottom